Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Breast Neoplasms, Neoplasms, Hormone-Dependent
About this trial
This is an interventional treatment trial for Breast Neoplasms focused on measuring Atamestane, Breast neoplasms, Combined hormonal therapy, Complete estrogen blockade, Ductal breast carcinoma, Estrogen blocker, Fareston®, Femara®, First line therapy, Letrozole, Lobular breast carcinoma, Locally advanced breast cancer, Locally recurrent breast cancer, Maximal estrogen inhibition, Metastatic breast cancer, Neoplasms, Hormone-dependent, Receptor-positive, Stage IIIA breast cancer, Stage IIIB breast cancer, Stage IV breast cancer, Toremifene
Eligibility Criteria
Inclusion Criteria: To be eligible to receive continued treatment, subjects must remain eligible to receive study drug at the time of their last Biomed 777-CLP-29 visit To continue on survival follow-up, subjects must be in survival follow-up in study Biomed 777-CLP-29 Written informed consent obtained for subjects who continue study drug treatment Exclusion Criteria: Subjects who have withdrawn consent to participate in Biomed 777-CLP-29 for any reason Subjects for whom the investigator considers study participation is no longer in the best interest of those subjects.